A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies

2018 ◽  
Vol 82 (3) ◽  
pp. 541-550
Author(s):  
Millie Das ◽  
Sukhmani K. Padda ◽  
Adam Frymoyer ◽  
Julian Molina ◽  
Alex Adjei ◽  
...  
Keyword(s):  
Phase I ◽  
Tyrosine Kinase Inhibitor ◽  
Small Molecule ◽  
Kinase Inhibitor ◽  
Pharmacokinetic Analysis ◽  
Two Phase ◽  
Dosing Schedule ◽  
Phase I Studies ◽  
Solid Malignancies ◽  
Continuous Dosing

scholarly journals Romidepsin and lenalidomide based regimens have efficacy in relapsed/refractory lymphoma: combined analysis of two phase I studies with expansion cohorts

2021 ◽  
Author(s):  
Neha Mehta‐Shah ◽  
Matthew A. Lunning ◽  
Alison J. Moskowitz ◽  
Adam M. Boruchov ◽  
Jia Ruan ◽  
...  
Keyword(s):  
Phase I ◽  
Two Phase ◽  
Phase I Studies ◽  
Combined Analysis ◽  
Refractory Lymphoma

Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study

2021 ◽  
Author(s):  
Katrina S. Pedersen ◽  
Patrick M. Grierson ◽  
Joel Picus ◽  
A. Craig Lockhart ◽  
Bruce J. Roth ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Phase I ◽  
Tyrosine Kinase Inhibitor ◽  
Solid Tumors ◽  
Phase I Study ◽  
Kinase Inhibitor

scholarly journals Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412

Cancer Cell ◽  
2002 ◽  
Vol 1 (5) ◽  
pp. 433-443 ◽  
Author(s):  
Ellen Weisberg ◽  
Christina Boulton ◽  
Louise M Kelly ◽  
Paul Manley ◽  
Doriano Fabbro ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Small Molecule ◽  
Kinase Inhibitor ◽  
Leukemia Cells

scholarly journals Relative Bioavailability of Orally Dispersible Tablet Formulations of Levo‐ and Racemic Praziquantel: Two Phase I Studies

2018 ◽  
Vol 12 (1) ◽  
pp. 66-76 ◽  
Author(s):  
Wilhelmina Maria Bagchus ◽  
Deon Bezuidenhout ◽  
Eleanor Harrison‐Moench ◽  
Elly Kourany‐Lefoll ◽  
Peter Wolna ◽  
...  
Keyword(s):  
Phase I ◽  
Relative Bioavailability ◽  
Two Phase ◽  
Phase I Studies ◽  
Dispersible Tablet ◽  
Tablet Formulations
Sign in / Sign up

Export Citation Format

Share Document